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Abstract
Background:  Monocytes can be primed in vitro by lipopolysaccharide (LPS) for release of
cytokines, for enhanced killing of cancer cells, and for enhanced release of microbicidal oxygen
radicals like superoxide and peroxide. We investigated the proteins involved in regulating priming,
using 2D gel proteomics.
Results: Monocytes from 4 normal donors were cultured for 16 h in chemically defined medium
in Teflon bags ± LPS and ± 4-(2-aminoethyl)-benzenesulfonyl fluoride (AEBSF), a serine protease
inhibitor. LPS-primed monocytes released inflammatory cytokines, and produced increased
amounts of superoxide. AEBSF blocked priming for enhanced superoxide, but did not affect
cytokine release, showing that AEBSF was not toxic. After staining large-format 2D gels with Sypro
ruby, we compared the monocyte proteome under the four conditions for each donor. We found
30 protein spots that differed significantly in response to LPS or AEBSF, and these proteins were
identified by ion trap mass spectrometry.
Conclusion: We identified 19 separate proteins that changed in response to LPS or AEBSF,
including ATP synthase, coagulation factor XIII, ferritin, coronin, HN ribonuclear proteins, integrin
alpha IIb, pyruvate kinase, ras suppressor protein, superoxide dismutase, transketolase,
tropomyosin, vimentin, and others. Interestingly, in response to LPS, precursor proteins for
interleukin-1β appeared; and in response to AEBSF, there was an increase in elastase inhibitor. The
increase in elastase inhibitor provides support for our hypothesis that priming requires an
endogenous serine protease.
Background
Priming of monocytes in vitro with LPS is a model for
macrophage activation, a key process in innate immunity.
Innate immunity protects us against infection before spe-
cific antibodies or specific T-cell responses can be
mounted. In experimental models of infection, activating
Published: 20 May 2008
Proteome Science 2008, 6:13 doi:10.1186/1477-5956-6-13
Received: 21 November 2007
Accepted: 20 May 2008
This article is available from: http://www.proteomesci.com/content/6/1/13
© 2008 Pabst et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.Proteome Science 2008, 6:13 http://www.proteomesci.com/content/6/1/13
Page 2 of 13
(page number not for citation purposes)
macrophages in animals with agents like muramyl dipep-
tide cures the animals of an otherwise lethal infection
[1,2]. The goal of this study was to better understand
monocyte activation by LPS. So, we examined the mono-
cyte proteome ± LPS ± AEBSF (4-(2-aminoethyl)-benze-
nesulfonyl fluoride), a serine protease inhibitor and an
inhibitor of priming for enhanced superoxide release [3]).
In our model of macrophage activation, we cultured
freshly isolated monocytes from normal adult blood
donors at 37° in 5% CO2 in chemically defined medium
(modified Earle's balanced salt solution, EBSS). Defined
medium and other precautions were designed to avoid
inadvertent contamination by bacterial products. All rea-
gents and equipment were tested for microbial contami-
nation by Limulus  assay. To avoid artefacts caused by
adherence to foreign surfaces, the monocytes were cul-
tured in suspension in Teflon bags. We used a highly puri-
fied E. coli LPS preparation that is free of contaminating
proteins [4], and that was active at a concentration of 2
ng/ml. (Actually, macrophages require only 1 to 10 mole-
cules of this LPS per monocyte to become primed for
enhanced release of superoxide [5]. This is a remarkable
example of amplification in signal transduction in which
10 molecules of LPS enable the release of 10 billion mol-
ecules of superoxide. This is also a reminder of the likely
range of concentrations of proteins involved in priming.)
In this model, we investigated the specific effects of add-
ing LPS to monocytes in vitro. We expected fewer changes
in the proteome compared with experimental systems
that involve more complex biological changes, such as
activation of macrophages in vivo by infection, or differ-
entiation of monocytes into dendritic cells [6] or alveolar
macrophages [7], or differentiation of a leukemic cell line
[8]. Because we were looking at a small specific step (addi-
tion of LPS in vitro), we expected that changes seen in the
proteome would have a high probability of being related
to LPS priming.
Our model has a weakness in that we must wait some
period of time (24–48 h) for freshly isolated monocytes to
become fully quiescent with respect to priming for
enhanced phorbol myristate acetate-triggered release of
superoxide. Thus, we are mixing the effects of priming in
the LPS-treated cells with the process of quiescence in the
control cells. In our model, we added LPS at the beginning
of culture, although we could have waited until the cells
were quiescent before adding LPS. However, pure LPS, at
low concentrations (2 ng/ml), takes at least 6–12 h to
prime monocytes, extending the incubation time to 30–
60 h. After 30–60 h, unprimed non-adherent and non-
contaminated monocytes begin to undergo apoptosis, so
we preferred mixing priming with quiescence rather than
with apoptosis. We believe our model is a reasonable
choice, but other models of macrophage and neutrophil
activation have their own advantages. For example, neu-
trophils respond much faster to priming by LPS, and they
don't require a period of incubation to achieve quiescence
[9]. Monocytes respond more quickly to cytokines than to
LPS [10,11].
Earlier work led us to form the hypothesis that priming of
monocytes by LPS for enhanced release of microbicidal
oxygen radicals like superoxide and peroxide was regu-
lated by a negative regulator protein that normally kept
the monocytes in check. Thus, any sort of infection,
inflammation, or environmental stimulus leads to the
activation of a protease that cleaves the negative regulator
and allows the monocytes to produce large amounts of
oxygen radicals. We found that bacterial products like LPS
or muramyl dipeptide, cytokines like interferon-gamma,
environmental challenges like gamma radiation, low pH,
or hypertonicity, all prime monocytes for enhanced
release of superoxide [12-14]. Our earlier work showed
that macrophages could be primed by exposure to the ser-
ine proteases elastase and cathepsin G from neutrophils
[15]. Priming by serine proteases, and blockade of prim-
ing by AEBSF [3], led us to suggest that proteolytic cleav-
age by a serine protease is part of the mechanism of
monocyte priming for enhanced superoxide release
(although not required for cytokine release). We hoped
this proteomic study would show us the negative regula-
tor, the protease, or some related protein. In fact, we
found that LPS caused an increase in intracellular precur-
sors for IL-1β, although earlier we showed that secretion
of cytokines was not required for priming for superoxide
[16]. We also found an increased amount of elastase
inhibitor, when monocytes were treated with AEBSF. We
suggest the hypothesis that AEBSF prevents the consump-
tion of elastase inhibitor by inactivating the protease
(elastase or some other serine protease) that regulates
priming for superoxide. Of course, AEBSF inhibition of
other serine proteases that are not related to priming
might also contribute to the increase in elastase inhibitor.
Results
Cytokine release
LPS-primed monocytes released inflammatory cytokines,
including interleukin-1beta (IL-1β), IL-6, IL-8, IL-10,
tumor necrosis factor alpha (TNFα), and granulocyte/
macrophage colony stimulating factor (GM-CSF) (Figure
1). Taking IL-1β as an example, monocytes produced
almost no IL-β in the absence of LPS (< 0.2 ng/ml of cul-
ture medium), whereas LPS-primed monocytes secreted
14 ± 1.5 ng/ml (mean ± SE, n = 4, P < 0.001 by ANOVA).
Cytokines produced by lymphocytes, such as interferon
gamma, were not found, showing that the monocyte pop-
ulations were reasonably pure. AEBSF did not affect
cytokine release, showing that AEBSF did not adverselyProteome Science 2008, 6:13 http://www.proteomesci.com/content/6/1/13
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Effects of LPS and AEBSF on cytokine secretion by monocytes Figure 1
Effects of LPS and AEBSF on cytokine secretion by monocytes. Four of the ten cytokines assayed in culture medium 
from monocytes cultured for 16 h ± LPS ± AEBSF are shown. The first bar is Time 0, a control of monocyte medium taken at 
the start of culture. The last two bars show the effect of AEBSF added at the end of the culture at 16 h. Results are means ± SE, 
n = 4 donors. LPS was required for cytokine expression; AEBSF did not interfere, except that AEBSF added at the end of the 
experiment did reduce TNFα secretion. IL-8 and IL-10 responses were similar to IL-1β and IL-6 (not shown).
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affect the viability, or the protein synthesis and secretion
mechanisms of the monocytes. (An anomaly was that
AEBSF added at the end of the experiment, but not at the
beginning, did reduce TNFα.) In earlier work, we showed
that LPS-induced secretion of cytokines could be blocked
by corticosteroids like dexamethasone [16].
Superoxide release
The success of LPS priming was also measured by deter-
mining the increase in phorbol myristate acetate-triggered
release of superoxide (Figure 2). Monocytes incubated for
16 h without LPS produced 9.6 ± 0.9 nmol of superoxide
per million cells, whereas monocytes primed with LPS
produced 20.0 ± 1.0 nmol (mean ± SE, n = 4, P < 0.001 by
ANOVA). (Even under these endotoxin-free, non-adher-
ent culture conditions, monocytes become primed by the
trauma of the isolation procedure, so the unprimed cells
still produced considerable superoxide after 16 h. In our
earlier paper [17], we incubated the cells for 48 h, allow-
ing the unprimed monocytes to become more quiescent.
Here we wished to capture earlier events in priming, so we
accepted a less dramatic difference between unprimed and
primed monocytes in superoxide release.)
AEBSF blocked priming for enhanced superoxide release.
When AEBSF was added to unprimed monocytes, super-
oxide release was reduced to 5.5 ± 1.5 nmol; and when
AEBSF was added to LPS-primed monocytes, superoxide
was reduced to 2.7 ± 0.3 nmol (P < 0.001 for the effects of
both LPS and AEBSF by ANOVA). AEBSF had only a small
effect when added at the end of the 16 h incubation with
LPS (16.6 ± 0.3 nmol versus 20.0 ± 1.0 nmol with no
AEBSF). This small effect showed that AEBSF did not inter-
fere with triggering by phorbol myristate acetate or with
the superoxide assay itself.
Proteomes
For each donor, duplicate 2D gels were run on monocytes
treated ± LPS and ± AEBSF. After careful visual inspection
to remove debris, bubbles, or speckles of Sypro ruby from
the gel images, approximately 1000 protein spots were
quantified on each gel by PDQuest software. The density
for each spot was normalized against the total spot quan-
tity in the valid protein spots on each gel, using PDQuest.
After ANOVA on the means of the spot densities from the
duplicate gels from all four donors and all treatments,
thirty differentially expressed proteins were found to be
statistically significant (P < 0.05) and were studied fur-
ther. Representative gel images are shown in Additional
Files 1, 2, 3 and 4. The identities of the proteins that
responded to LPS or AEBSF are shown in Table 1.
The pattern of response fell into 4 categories:
1) Increased expression after LPS, with the increase
blocked by AEBSF, shown as "↑LPS" in Table 1.
2) Decreased expression after LPS, with the decrease
blocked by AEBSF: "↓LPS"
3) Spot absent or minimal after treatment with AEBSF ±
LPS: "↓AEBSF"
4) Spot present only after treatment with AEBSF ± LPS:
"↑AEBSF"
Effects of LPS and AEBSF on phorbol-triggered superoxide  release Figure 2
Effects of LPS and AEBSF on phorbol-triggered 
superoxide release. Phorbol myristate acetate-triggered 
release of superoxide from monocytes cultured for 16 h ± 
LPS ± AEBSF. The first bar is Time 0, a control of monocytes 
at the start of culture when they were still agitated by the 
isolation procedure. The last two bars show the effect of 
AEBSF added at the end of the culture at 16 h. LPS primed 
monocytes for enhanced release of superoxide; AEBSF 
blocked priming. Means ± SE, n = 4.
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An example of each behavior is shown in Fig 3. Logically,
other behaviors were possible, but we did not observe
them.
Among the 30 differentially expressed protein spots on
the gels, we identified 19 different proteins whose expres-
sion changed in response to LPS or AEBSF (Table 1).
(Although all 30 spots were identified by mass spectrom-
etry, some of the spots represented different forms of the
same protein.)
In response to LPS, IL-1β precursors appeared in the 2D
gel (Fig. 3 and Additional File 5, spots A and B). IL-1β pre-
cursors decreased after treatment with AEBSF (Fig. 3 and
File 5). This observation was surprising, because AEBSF
did not affect the secretion of mature IL-1β, as measured
by the multiplex immunoassay (Fig. 1). Perhaps AEBSF
interfered with the formation of this particular precursor
form, but did not block alternative pathways to mature IL-
1β. When AEBSF was added at the end of the 16 h incuba-
tion, it had no effect (Fig. 3). The observed molecular
weights of spots A and B on the gels corresponded to a
precursor form of IL-1β (34–35 kDa, compared with 17
kDa for the secreted form). Ion trap MS/MS also showed
that spots A and B contained the precursor form of IL-1β.
IL-1β has a propeptide of 116 amino acids. For spot A, we
identified a peptide ISDHHYSK (11 of 14 possible b and
y ions) from the precursor amino-terminus of IL-1β
(amino acids 52–59). In spot B, we identified ISDHHYSK
and also QAASVVVAMDK (63–73). In both A and B, we
identified SLVMSGPYELK (133–143) (15 of 20 ions),
which is part of the secreted protein. In spot A, we also
found DDKPTLQLESVDPK (191–204) (18 of 26 ions)
and FVFNIEINNK (215–225) (16 of 20 ions).
Another interesting finding was that AEBSF increased leu-
kocyte elastase inhibitor (spot H) (Fig. 3, Table 1 and
Additional File 5). This protein was definitively identified
by ion trap MS/MS in two independent experiments from
two donors. Spot H appears to contain the intact leuko-
cyte elastase inhibitor. The molecular weight estimate
from the gel was 40 kDa, compared with a theoretical
mass of 42,742 Da with 379 amino acids. We have ion
trap sequence data for 5 independent peptides: TYNFLPE-
FLVSTQK (97–110) (21 of 26 b and y ions), EATTNAPFR
(178–186) (14 of 16 ions), LGVQDLFNSSK (291–301)
Table 1: Monocyte proteins altered by LPS or AEBSF. Sorted by Protein ID. Arrows indicate that the protein increased or decreased 
after LPS or AEBSF
Behavior Spot Swiss-prot Protein ID MW Gel MW Theory pI Gel pI Theory
↑AEBSF K P07355 Annexin A2 34,000 38,604 8.9 7.57
↓AEBSF Z P07355 Annexin A2 29,000 38,604 8.3 7.57
↑LPS N P08758 Annexin A5 34,000 35,937 5.2 4.94
↑AEBSF 3Z P08758 Annexin A5 101,000 35,937 6.4 4.94
↑AEBSF J P25705 ATP synthase alpha chain, mitochondrial precursor 50,000 59,751 8.9 9.16
↓LPS M P25705 ATP synthase alpha chain, mitochondrial precursor 26,000 59,751 8.6 9.16
↓LPS V P00488 Coagulation Factor XIII A chain precursor 90,000 83,267 6.2 5.75
↓AEBSF Q P31146 Coronin-1A 50,000 51,026 6.2 6.25
↑LPS F P02794 Ferritin heavy chain (N-acetyl) 25,000 21,226 5.7 5.31
↑AEBSF X P04406 Glyceraldehyde-3-phosphate dehydrogenase, liver 35,000 36,053 9.2 8.57
↑AEBSF Y P04406 Glyceraldehyde-3-phosphate dehydrogenase, liver 35,000 36,053 8.7 8.57
↓LPS P P68871 Hemoglobin, subunit beta 10,000 15,998 7.4 6.74
↑LPS 4Z P22626 HN ribonucleoproteins A2/B1 34,000 37,430 9.3 8.97
↓LPS T P08514 Integrin alpha-IIb precursor 130,000 113,391 5.1 5.21
↑LPS A P01584 Interleukin-1β precursor 34,000 30,748 4.9 4.70
↑LPS B P01584 Interleukin-1β precursor 35,000 30,748 4.8 4.70
↑AEBSF H P30740 Leukocyte Elastase Inhibitor 40,000 42,742 6.2 5.90
↓AEBSF W P07737 Profilin 12,000 15,054 7.9 8.44
↑AEBSF C P14618 Pyruvate Kinase, isozymes M1/M2 57,000 57,937 8.4 7.96
↑AEBSF I P14618 Pyruvate Kinase, isozymes M1/M2 60,000 57,937 9.0 7.96
↓AEBSF R P14618 Pyruvate Kinase, isozymes M1/M2 36,000 57,937 6.0 7.96
↓AEBSF 5Z P14618 Pyruvate Kinase, isozymes M1/M2 60,000 57,937 7.0 7.96
↓LPS 2Z Q15404 Ras suppressor protein 1 30,000 31,540 9.1 8.57
↑LPS G P04179 Superoxide dismutase – Mn 25,000 24,722 7.4 8.35
↓AEBSF L P29401 Transketolase 57,000 67,878 8.1 7.58
↑AEBSF U P29401 Transketolase 70,000 67,898 8.4 7.58
↓LPS D P09493 Tropomyosin alpha 1 chain 32,000 32,709 4.9 4.69
↑LPS O P08670 Vimentin 50,000 53,652 5.0 5.06
↑LPS S P08670 Vimentin 48,000 53,652 4.9 5.06
↓LPS E P08670 Vimentin (amino half) 24,000 53,652 4.6 5.06Proteome Science 2008, 6:13 http://www.proteomesci.com/content/6/1/13
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Effects of LPS and AEBSF on expression of IL-1β, elastase inhibitor, vimentin, and ATP synthase Figure 3
Effects of LPS and AEBSF on expression of IL-1β, elastase inhibitor, vimentin, and ATP synthase. Protein levels 
from 2D gels from monocytes cultured for 16 h ± LPS ± AEBSF are shown for four spots on the gels. The Y-axis represents 
integrated normalized spot intensity, as calculated by PDQuest. The first bar is Time 0, a control of monocyte cell protein 
taken at the start of culture. The last two bars show the effect of AEBSF added at the end of the culture at 16 h. Letters desig-
nate particular spots on the gel. Results are means ± SE from the last gel run involving the last two donors; results from the 
first two donors were similar. LPS increased the expression of the particular form of IL-1β precursor found in spot A, but 
decreased the vimentin spot E and the ATP synthase spot M. AEBSF enhanced expression of elastase inhibitor in spot H. 
Results from all 30 differing spots are provided in Additional File 5. Representative gels ± LPS ± AEBSF, with spots identified by 
letter, are shown in Additional Files 1, 2, 3 and 4.
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(17 of 20 ions), ADLSGMSGAR (302–311) (14 of 18
ions), and DIFISK (312–317) (8 of 10 ions). We also have
MALDI-TOF data for: FQSLNADINKR (70–80), TYNFLPE-
FLVSTQK (97–110), TYGADLASVDFQHASEDAR (111–
129), LVLVNAIYFK (159–168), EATTNAPFR (178–186),
FKLEESYTLNSDLAR (276–290), HNSSGSILFLGR (364–
375). If we permitted phosphorylation in the MALDI pep-
tide search, we added: FALDLFLALSENNPAGNIFISPFSIS-
SAMAMVFLGTR (11–47), HNSSGSILFLGRFSSP (364–
379), and LGVQDLFNSSK (291–301). These peptides fit
into the sequence range from amino acids 11 to 379. So,
in Spot H, we could be missing some of the amino-termi-
nus. We did not detect the peptide containing the putative
active site. According to the UniProtKB/Swiss Prot data
base entry P30740, the active site of leukocyte elastase
inhibitor is amino acids 344–345. The data provide an
indication, but not proof, that elastase inhibitor in spot H
might be phosphorylated.
AEBSF blocked the increase in superoxide dismutase-Mn
associated with LPS priming (spot G) (Table 1 and Addi-
tional File 5). AEBSF also blocked priming for phorbol-
triggered superoxide release, suggesting that superoxide
dismutase appeared in response to, or in anticipation of,
oxygen radical stress. AEBSF also eliminated ferritin (spot
F) that appeared in response to LPS (Table 1 and Addi-
tional File 5).
After identifying the proteins, we inferred that several pro-
teins changed position in the gel after LPS or AEBSF. For
example, vimentin appeared to move position in the 2D
gel in response to LPS priming. Vimentin, the intermedi-
ate filament protein, plays a role in macrophage differen-
tiation [18]. Our results suggested that vimentin was
increased by LPS priming (spots O and S at 48–50 kDa on
the gels), and that in the absence of LPS, vimentin was
cleaved into smaller fragments (spot E at 24 kDa on the
gels) (Table 1 and Additional File 5). In contrast, ATP syn-
thase appeared to be cleaved in response to LPS, and this
cleavage was blocked by AEBSF (compare results for spot
J at 50 kDa with spot M at 26 kDa) (Table 1 and Addi-
tional File 5). AEBSF caused transketolase spot L at 57 kDa
to disappear and spot U at 70 kDa to increase on the 2D
gels (Table 1 and Additional File 5).
Another example of altered position on the gel is Annexin
A5. Exposure of monocytes to AEBSF produced a spot cor-
responding to molecular weight 101,000 Da on the gel
(spot 3Z), compared with the theoretical molecular
weight of 35,937. Of course, this might be a misidentifica-
tion, but we found 9 independent peptides, all of which
belonged to annexin 5A. Annexin 5A was also found in
spot N at 34 kDa, and this spot was increased by LPS
(Table 1 and Additional File 5).
Discussion
This report supplements our previous paper on the pro-
teomics of monocyte priming [17]. Compared with our
previous paper, here we analyzed the monocytes at an ear-
lier time after addition of LPS (16 h versus 48 h) to detect
protein changes that occur earlier in the response to LPS.
LPS causes profound changes in monocyte cell structure
and function over time. Nevertheless, many similar pro-
tein changes were found in this report, compared with our
earlier paper. In that paper, we discussed the relevance of
these similar altered proteins to macrophage activation,
including superoxide dismutase, annexins, transketolase,
pyruvate kinase, and integrin alpha IIb. However, in the
earlier paper, because we allowed the events initiated by
LPS to unfold for 48 hours, some of the changes that we
found may have been rather distant from the initial criti-
cal events of priming. In contrast, the results in Table 1
presented here represent changes that occurred early in
the response to LPS. Also, on the technical side, we used a
less dense 2D gel (12% versus 13% acrylamide/bis) to bet-
ter separate higher molecular weight proteins (at the cost
of losing some lower MW proteins). We also used Sypro
ruby fluorescent stain in place of Coomassie blue stain to
increase the sensitivity of detection of less abundant pro-
teins. So our previous paper detected some different
changes because the effects of LPS had more time to
develop, and we were also able to detect changes in some
lower molecular weight proteins. The present study
detected some different proteins because of greater sensi-
tivity of gel staining and better resolution of higher molec-
ular weight proteins, and because we focused on earlier
responses to LPS. Because of these differences between the
two studies, comparing the results reported here with
those of our previous paper requires some caution and
careful thought. A valid time course would require a much
bigger study with consistent methodology.
With these caveats in mind, compared with our previous
paper, here we found some interesting new protein alter-
ations. The new protein changes included ATP synthase,
coagulation factor XIII, coronin, elastase inhibitor, ferri-
tin, glyceraldehyde-3-phosphate dehydrogenase, HN
ribonuclear proteins A2/B1, profilin, ras suppressor pro-
tein, tropomyosin, and vimentin. In particular, in
response to LPS, we saw intracellular precursors of inter-
leukin-1β, one of the most important cytokines elicited by
LPS. This observation demonstrated that proteomic anal-
ysis could detect changes relevant to macrophage activa-
tion.
Jin and colleagues have presented an excellent proteomic
reference map of the proteins of blood monocytes [19].
Most the proteins that we detected appear on their map,
and they appear in the corresponding locations. Their list
includes proteins that we found in unprimed monocytes,Proteome Science 2008, 6:13 http://www.proteomesci.com/content/6/1/13
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like integrin alpha IIb, a protein that disappears after LPS
priming [17]. However, their map does not include a
number of other proteins that we found to decrease after
LPS priming, like coagulation factor XIII and ras suppres-
sor protein. So it is possible that their monocytes were still
primed to some extent by their experimental procedures.
Priming or activation must be closely regulated so that a
vigorous response to infection can be mounted, while
limiting tissue damage by oxygen radicals and cytokines
once the infection is controlled. There is abundant evi-
dence for an important role for phosphorylation cascades
in regulating the activation of leukocytes [20]. However,
in addition to the activity of kinases and phosphatases, we
proposed the hypothesis that priming of monocytes in
vitro, and also activation of monocytes in vivo in response
to infection or inflammation, depends upon the activa-
tion of an endogenous protease. Over many years, we
attempted to inhibit LPS-priming of monocytes with a
wide range of inhibitors, but found inhibition with only
two compounds, both protease inhibitors, the most effec-
tive being AEBSF [3], an irreversible serine protease inhib-
itor.
Because AEBSF was the best inhibitor of priming that we
found, we hypothesized that priming depended upon the
activation of an endogenous protease. We undertook this
proteomic analysis to identify the protease or to identify
an endogenous inhibitor that keeps that protease from
activating monocytes until they are needed to combat
infection. We did not observe any change in abundance
for any proteases, nor did we come across any proteases
covalently modified by AEBSF. However, we saw that
AEBSF added to monocytes in vitro caused an increase in
the abundance of an endogenous protease inhibitor, leu-
kocyte elastase inhibitor. We speculate that a smooth con-
tinuous synthesis of elastase inhibitor is required to
maintain monocytes in an unprimed state. If a sufficient
amount of endogenous protease is activated (by phospho-
rylation, for example, and we found alterations in kinases
and their substrates), the elastase inhibitor is consumed,
and some of the protease survives and causes activation.
Alternatively, phosphorylation or dephosphorylation
might inactivate the endogenous inhibitor. (We found
that elastase inhibitor in spot H was probably phosphor-
ylated.) So, perhaps, elastase inhibitor is a negative regu-
lator of activation. AEBSF might prevent the destruction of
this endogenous inhibitor that normally takes place in
response to priming by LPS or other priming agents. (Of
course, logically, increasing the elastase inhibitor might
be a second effect of AEBSF, unrelated to the ability of
AEBSF to inhibit priming.) The endogenous leukocyte
elastase inhibitor inhibits both serine and cysteine pro-
teases, unlike AEBSF which is specific for serine proteases.
If elastase inhibitor is responsible for blocking priming for
enhanced release of superoxide, the endogenous protease
that might be involved in regulating priming could be
either a serine protease or a cysteine protease. However, if
AEBSF acts directly on the relevant protease, not just indi-
rectly by sparing elastase inhibitor, then the relevant pro-
tease is probably a serine protease.
Regarding the effects of AEBSF on the proteome compared
with cytokine secretion, we found that AEBSF had no
effect on secretion of IL-1β or the other cytokines, whereas
AEBSF blocked the formation of the IL-1β precursors
found in spots A and B. We have a direct comparison only
with IL-1β, because no other cytokines were detected in
the proteome. We suggest that AEBSF inactivated a serine
protease that created spots A and B, but that an alternative
processing, perhaps involving a non-serine protease,
allowed mature IL-1β to be secreted. These apparently
conflicting results are surprising, but they were obtained
in the same experiments with the same monocyte cul-
tures, assaying simultaneously the secreted cytokines in
the medium and analyzing the monocyte cellular pro-
teomes.
Although AEBSF did not affect cytokine release, we
showed in earlier work that AEBSF or corticosteroids
block priming by LPS for enhanced killing of leukemic
cells [21], even though killing of leukemic cells does not
require oxygen radicals [22]. So the effects of AEBSF on
priming extend beyond superoxide.
We have some speculations about some of the other
altered proteins. The high apparent mass of spot 3Z at 101
kDa suggests that AEBSF caused annexin 5A to become
conjugated with itself or possibly with another unidenti-
fied protein. As their name suggests, the annexins do bind
other proteins and lipids.
AEBSF decreased ATP synthase in spot M at 26 kDa and
increased ATP synthase in spot J at 50 kDa, which is closer
to the theoretical mass of 59,751 Da, suggesting that
AEBSF blocked ATP synthase degradation. Besides its role
in oxidative phosphorylation, ATP synthase might have
an unknown direct role in priming. Because there are only
about 25,000 human genes [23], many proteins have
multiple functions. For example, we now know that mito-
chondrial cytochrome c, long studied as part of the elec-
tron transport system, is also a key regulator of apoptosis
in mouse macrophages [24,25]. It would not be surprising
if ATP synthase, another mitochrondrial enzyme, also has
a direct role in responses to LPS.
In our study, LPS caused the disappearance of Factor XIII
(spot V). Coagulation Factor XIII is a transglutaminase
that crosslinks fibrin. As a class, transglutaminases have
many functions, and so Factor XIII might have other intra-Proteome Science 2008, 6:13 http://www.proteomesci.com/content/6/1/13
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cellular roles besides its well known role in stabilizing
blood clots. There must also be a function for this protein
inside monocytes.
Ras suppressor protein 1 blocks the ras signal transduc-
tion pathway [26]. LPS increases active ras-GTP in macro-
phages [27]. Disappearance of the suppressor protein in
response to LPS (spot 2Z) suggests that LPS activated the
ras pathway.
This study is far from the last word on the proteomics of
macrophage activation. A more extensive time course,
from 1 minute to 48 hours after addition of LPS, is
needed; and this time course study should utilize a con-
sistent state-of-the-art methodology. Methods other than
2D gels should be attempted. Priming agents other than
LPS, like muramyl dipeptide and interferon gamma,
should also be examined over time. Other models of mac-
rophage activation should be studied, including the
effects of in vivo activation of macrophages. Because of the
importance of macrophage activation in resistance to
infection and in killing cancer cells, these more extensive
studies are warranted.
The utility of protease inhibitors like AEBSF as anti-
inflammatory drugs remains unknown. Their potential
benefits might be overshadowed by side-effects and the
risks involved in inhibiting useful host-defence processes.
However, it is noteworthy that AEBSF is well-tolerated in
animal models [28].
Infectious diseases remain a major problem, due to aging
of the population, increased numbers of immuno-com-
promised patients, and increasing resistance of microbes
to antibiotics. Thus, it is important to boost the innate
infection-fighting abilities of our immune system. In cell
culture and in animal models, we demonstrated that
agents that activate macrophages enhance resistance to
infection, and that protease inhibitors can block activa-
tion. On the other hand, excessive or prolonged macro-
phage activation, in autoimmune diseases for example,
leads to tissue destruction. To correct defects in macro-
phage activation in human patients we need to know
more about the mechanisms that control macrophage
activation.
Conclusion
In a carefully constructed in vitro model of macrophage
activation, proteomic analysis revealed that monocytes
primed with LPS accumulated intracellular precursors of
the key cytokine interleukin-1β. When the priming for
enhanced release of oxygen radicals like superoxide was
inhibited by AEBSF, an increase in endogenous elastase
inhibitor was found. The increase in the elastase inhibitor
is consistent with a role for proteolysis in the mechanism
of macrophage activation.
Methods
Monocytes
Blood was drawn from 4 healthy adult donors at Life-
blood Regional Blood Center in Memphis. The protocol
was approved by the University of Tennessee Human Sub-
jects Institutional Review Board. The leukocyte-rich "buffy
coats" were isolated by centrifugation, and immediately
brought to our laboratory. Monocytes were passively iso-
lated from the buffy coats by RosetteSep (Stem Cell Tech-
nologies, Vancouver, Canada), a passive selection
technique that does not activate the monocytes. This pro-
cedure removed all leukocytes other than monocytes from
the cell suspension by crosslinking them to red cells, leav-
ing the monocytes undisturbed. After incubation with the
RosetteSep crosslinking antibodies, the cell suspension
was layered over Histopaque 1077 (Sigma) and centri-
fuged, so that red cells and crosslinked white cells pel-
leted, and the monocytes remained in suspension. EDTA
(1 mM) was the anti-coagulant. Cells were counted with a
hemocytometer, and the purity of the monocyte popula-
tion was assessed by microscopic examination and by
esterase staining, and found to be >95%. Monocytes were
cultured 16 hours overnight ± LPS (2 ng/ml from E. coli
K12) ± AEBSF (250 µM) in modified Earle's balanced salt
solution (EBSS) at 37°C in 5% CO2 in Teflon bags. The
LPS was given by Floyd C. McIntire of the University of
Colorado. AEBSF was purchased from Calbiochem EMD
Biosciences Inc., San Diego, CA. Each culture contained 2
million monocytes in 2 ml of medium, corresponding to
200 µg of protein (Lowry method). All reagents used in
isolation and culture were endotoxin-free by Limulus
assay. Solutions were prepared with sterile pyrogen-free
bottled "water for irrigation" (Baxter Healthcare, Deer-
field, IL, USA). Before use, Teflon bags were baked at 200°
for 2 h to destroy any microbial contaminants. Passive
separation, absence of contamination, and Teflon are all
important to prevent inadvertent activation of monocytes.
Multiple cultures were prepared for each experimental
condition from each of the donors; one culture was used
for confirmation of priming by measuring cytokines and
another for measurement of superoxide release, and two
cultures were used for duplicate samples for 2D gels.
Monocytes from each donor were isolated and cultured in
separate experiments performed on different days.
Cytokines
Monocyte culture media were assayed for 10 cytokines by
Multiplex Bead Immunoassay (using a Luminex reader,
Bio-Rad, Hercules, CA, USA, and an assay kit from Bio-
Source-Invitrogen, Carlsbad, CA, USA). If monocytes are
cultured in endotoxin-free non-adherent conditions, they
will produce detectable levels of inflammatory cytokinesProteome Science 2008, 6:13 http://www.proteomesci.com/content/6/1/13
Page 10 of 13
(page number not for citation purposes)
only after exposure to LPS. By measuring the fluorescence
intensity of beads of various infrared "colors", with each
color having a cytokine-specific antibody, cytokines like
IL-1β, IL-6, IL-8, TNFα, and GM-CSF in the culture media
from the four treatment groups (± LPS ± AEBSF) and from
multiple donors were quantified simultaneously in the
same assay.
Superoxide
The ability of monocytes to produce superoxide was deter-
mined as a further measure of monocyte priming. Super-
oxide was assayed spectrophotometrically. Sample
monocyte cultures were treated with cytochrome c, which
changes color from orange to pink when cytochrome c is
reduced by superoxide. Superoxide production was trig-
gered in the monocytes by addition of phorbol myristate
acetate (1 µM), a phytotoxin that directly activates protein
kinase C and triggers superoxide release. Using a Cary 300
spectrophotometer (Varian, Palo Alto, CA, USA), the
height of the absorbance peak of reduced cytochrome c
was measured at 550 nm, and compared with isosbestic
points at 542 nm and 556 nm (wavelengths at which the
absorbance does not change during oxidation-reduction).
Because cytochrome c has a narrow absorbance peak, this
analysis required a spectrophotometer with wavelength
accuracy of 0.5 nm and wavelength resolution of 0.5 nm.
The extinction coefficient for reduced versus oxidized
cytochrome c of 0.021 µM-1  was used to calculate
nanomoles of superoxide released per million monocytes.
2D gels
Monocytes from each of the cultures in Teflon bags were
washed with saline, and pelleted by centrifugation. The
monocytes in the pellet were digested with 0.1 ml of a
solution containing urea (7 M), thiourea (2 M), and
CHAPS detergent (4%). Using a Reduction-Alkylation kit
(Bio-Rad, Hercules, CA, USA), the protein disulfide bonds
were reduced with tributylphosphine, and alkylated with
iodoacetamide. The samples were then treated with a 2D
Clean-Up kit (Bio-Rad), which precipitated the proteins
with organic solvents, removing small molecules. These
kits were essential for good resolution in the pH 8–10
range on the 2D gels. The cleaned-up protein pellets were
dissolved in 400 µl of "rehydration buffer". Rehydration
buffer contained urea (7 M), thiourea (2 M), CHAPS
(4%), 30 µl of 100× ampholytes pH 3–10 (Bio-Rad), and
bottled water-for-irrigation in a final volume of 3 ml.
The cellular proteins were separated using large-format
2D gels (20 cm × 20 cm × 1 mm), with a pH range of 3–
10, and a useful molecular weight range of 10–250 kDa.
For the first dimension, 350 µl of each sample was pipet-
ted into a 12 slot tray. Isoelectric focusing strips (ReadyS-
trip, 17 mm, pH 3–10, linear, Bio-Rad) were placed face
down onto the samples, and the strips were allowed to
rehydrate and absorb the samples overnight. Care was
taken to ensure that the strips did not adhere to the trays,
which might interfere with even rehydration. The tray was
wrapped in plastic with a slightly damp paper towel
included to prevent evaporation of the samples. The first
dimension was run in a Bio-Rad Protean IEF cell. Samples
were subjected to isoelectric focusing for a total of more
than 80,000 kVh, with a slow ramp-up of voltage 200 V to
10,000 V over 1 h, then 10,000 V for 8 h. The focused
strips were then subjected to a second round of reduction
and alkylation, using dithiothreitol (130 mM) and iodoa-
cetamide (135 mM), for 10 min in each solution, with 3
ml of each solution in each slot of a 12 slot tray.
For the second dimension of SDS-PAGE, 2D gels were run
12 at a time using the Bio-Rad Protean plus Dodeca sys-
tem. The Dodeca cell for the second dimension was criti-
cal for producing gels that were sufficiently reproducible
to allow the PDQuest software to make objective compar-
isons of spot intensities without significant human inter-
vention or bias. We cast 12% gels, containing 198 ml of
40% acrylamide/bis (29:1), 165 ml of Tris-HCl, pH 8.8,
and 297 ml of bottled water, for a total volume of 660 ml.
The solution was degassed with a vacuum pump for 5
min, 3.3 ml of 10% ammonium persulfate and 165 µl of
TEMED were added and gently swirled into the mixture.
The gel mixture was added to the casting chamber, and the
cassettes were filled from the bottom. Water was added to
the top of the gels with a 12-tip pipetter to prevent
"waves" as the gels polymerized. Running buffer was
added to the Dodeca unit, and maintained at 15–20° with
a high capacity (>400 watts) refrigerated circulator. Run-
ning buffer (25 liters) contained Tris base (25 mM), gly-
cine (192 mM), and sodium dodecyl sulfate (0.1%) (pH
8.3). The focused strips were dipped in 2D gel running
buffer. The damp strip was placed on the glass near the top
of the gel in the cassette, 5 ml of hot agarose (0.5%) was
added to the top of the gel, and the strips were pushed
down into the agarose. On either side of the strip, filter
paper squares (2 mm × 2 mm) containing 2 µl of protein
standards were also pushed into the agarose before it
hardened. The cassettes were placed sideways into the
Dodeca apparatus, where electrophoresis moved proteins
from the right to the left. Electrophoresis was conducted
at 200 V for 400 min.
Gels were removed from the cassettes and allowed to fall
gently into 250 ml of 10% methanol, 7% acetic acid in
plastic trays. Gels were rocked gently for 30 min. The gels
were stained for 4 hours with Sypro ruby, washed for 30
min with 10% methanol, 7% acetic acid, and washed
finally in water, and stored in the refrigerator. The wet gels
were scanned on a BioRad FX fluorescence scanner. Gels
from each of the donors were analyzed and compared
using PDQuest software. The results from all four donorsProteome Science 2008, 6:13 http://www.proteomesci.com/content/6/1/13
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were later compared and analyzed by ANOVA (see Statis-
tical analysis below).
The protein spots were manually cut from the wet gels,
using a UV light box to visualize the orange-red fluores-
cent spots, and using pipette tips, cut to the appropriate
diameter, as punches. The gel plugs were washed with
water, and incubated in ammonium bicarbonate (200
mM, pH 8.5) for 20 min. After the incubation, the gel
plugs were dehydrated with acetonitrile, and were dried in
a vacuum centrifuge. Each dried gel plug was rehydrated
with 20 µl of 50 mM ammonium bicarbonate containing
sequencing-grade trypsin (Promega, Madison, WI, USA)
at a concentration of 16.7 ng/µl. Digestion was carried out
overnight at 37°C. The trypsin-digested samples were cen-
trifuged, and the supernatants were collected and placed
in siliconized Eppendorf test tubes (Fisher Scientific, Pitts-
burgh, PA, USA). To extract residual peptides, a solution
of 35% water/60% acetonitrile/5% trifluoroacetic acid
was added to the remaining gel plugs, the samples were
subjected to an ultrasonic water bath for 20 min, and cen-
trifuged (12,000 × g for 1 min). Following centrifugation,
the supernatants were recovered, and were combined with
the previously collected supernatants. The tryptic peptides
were dried in a vacuum centrifuge. Before the nanoLC-
MS/MS analysis, each digest was purified with a ZipTip
C18 microcolumn (Millipore, Bedford, MA, USA). The
resulting peptides were eluted from the ZipTip with 3 µl
of 50% water/50% acetonitrile/0.1% trifluoroacetic acid.
After elution, each sample was diluted with 3 µl of water/
0.1% trifluoroacetic acid.
Mass spectrometry
Proteins were identified by liquid chromatography-nano-
electrospray ionization quadrupole ion trap mass spec-
trometry, using an LCQ Deca or an LCQ Deca XP Plus
mass spectrometer (ThermoElectron, San Jose, CA, USA)
to obtain MS and MS/MS spectra. Immediately following
the ZipTip purification, samples were manually injected
through a 6-port NanoPeak valve (M-485) from
Upchurch Scientific (Oak Harbor, WA, USA), fitted with a
2 µl capillary PEEK (polyether ether ketone plastic) sam-
ple loop. The samples were loaded onto a 75 µm I.D. (360
µm O.D., 15 µm tip, 10.5 cm length) Picotip capillary col-
umn/spray needle (New Objective, Woburn, MA, USA)
packed in-house with MAGIC C18 reversed-phase mate-
rial (5 µm, 200 Å) from Michrom Bioresources (Auburn,
CA, USA). Chromatography started with a 5 min initial
isocratic step of 100% A, followed by a linear 0–90% B
gradient for 40 min, followed by 25 min of 90% B. (A =
water with 2% methanol and 0.1% formic acid; B = 90%
methanol, 10% water and 0.1% formic acid). Peptides
were eluted with a 200 nl/min flowrate. Spectra were
acquired with the instrument operating in the data-
dependent mode. The instrument cycled through the
acquisition of a full-scan mass spectrum, followed by MS/
MS scans of the five most prominent ions after collision
with helium gas. Results were analysed with SEQUEST
software (Sequest Technologies, Lisle, IL), which matched
observed peptide masses and product ion masses with the
theoretical values for all proteins from humans in the Uni-
Prot/Swiss Protein database [29]. A maximum of one
missed cleavage was allowed, and the isotopic resolution
of the experimental masses was specified as monoiso-
topic. The experimental pI and MW from the gels were not
used to restrict the SEQUEST search. Modifications speci-
fied in the search were that cysteine was carbamidometh-
ylated, and that methionine could be oxidized.
Identification required an Xcorr ≥ 2.50 for doubly charged
ions for at least two independent peptides.
As a supplement to ion trap mass spectrometers, Matrix
Assisted Laser Desorption/Ionization Time-of-Flight
(MALDI-TOF) mass spectrometers were used for peptide
mass fingerprinting. The purified tryptic peptide samples
were mixed with a matrix of α-cyano-4-hydroxycinnamic
acid, spotted on a metal plate coated with paraffin wax
[30], allowed to dry, and washed. The plate was loaded
into a Voyager DE-RP MALDI-TOF (Applied Biosystems,
Foster City, CA) or a Bruker Ultraflex MALDI-TOF/TOF
mass spectrometer (Bruker Daltronics, Billerica, MA). The
mass-to-charge ratio (m/z) was determined for each pep-
tide (in these conditions, z = 1). The masses of the tryptic
peptides were determined from the mass spectrum pro-
duced, and compared with the theoretical masses of tryp-
tic peptides from all known human proteins to establish
the identity of the proteins of interest. MS-Fit [31] or Mas-
cot [32] and the UniProt/SwissProt database [29] were
used for protein identification. Masses were monoiso-
topic, cysteines were carbamidomethylated, and one
missed cleavage was allowed. Possible modifications con-
sidered were oxidation of M, N-terminal gln to pyroglu,
N-terminus acetylated, and phosphorylation of S, T, or Y.
(The second time-of-flight capability of the Bruker instru-
ment, which determines the mass of fragments of the tryp-
tic peptides, was not used for these experiments.)
Statistical analysis
From each donor and each treatment, monocyte protein
digests were prepared and run on duplicate gels. The
images of each gel were compared with PDQuest software,
which determined the densities (volume by Gaussian
integration) of each of the protein spots on the gels. The
two gels from the same sample gave spot densities that
differed only slightly (standard deviation < 10%). Any
greater deviation was an indication of a spot mismatch,
which was corrected. For each donor, the PDQuest analy-
sis was then used to examine whether any of the spots
changed in density as a result of treatment ± LPS ± AEBSF.
The means of the spot densities of the spots that changedProteome Science 2008, 6:13 http://www.proteomesci.com/content/6/1/13
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in all 4 donors were then subjected to analysis of variance
(ANOVA) followed by Scheffe's F-test to determine
whether any individual differences in protein expression ±
LPS ± AEBSF were significant at P < 0.05 level, with N = 4.
Each of the 30 proteins listed in Table 1 showed signifi-
cant differences by this analysis. (ANOVA corrects for the
problem of the large number of protein spots being ana-
lysed, so that 1 in 20 results (P < 0.05) are not assigned sig-
nificance by random chance.) Two of the donors did not
yield sufficient monocytes to allow for the particular con-
trols involving AEBSF added only after the 16 h incuba-
tion ± LPS, so N = 2 for those particular controls. Although
those controls were included in the overall ANOVA anal-
ysis, the results from those controls should not be overly
relied upon. Of course, statistical significance does not
mean biological importance. In the Discussion here and
in our previous paper [17], we try to evaluate the biologi-
cal importance of the statistically significant changes that
we observed.
Competing interests
The authors declare that they have no competing interests.
Authors' contributions
The study was designed by MJP; executed by MJP, KMP,
and DBH; and the mass spectrometry was performed and
interpreted by SBG and FG. All authors read and approved
the final manuscript.
Additional files
The four 2D gel image files (Additional Files 1, 2, 3 and 4)
should be viewed on a high quality large monitor, using
200–600% magnification as provided by Acrobat Reader.
A print-out on paper fails to convey the resolution or bit-
depth of the images and over-emphasizes streaking. The
original scanned images from the FX fluorescence scanner
have thousands of levels of fluorescence and 3.1 million
pixels, and these were the images actually used in the
PDQuest analysis.
Additional material
Acknowledgements
This paper is dedicated to the late Professor Floyd C. McIntire, who trained 
the senior author MJP in the ways of LPS. He prepared the highly purified, 
highly active LPS used in this study. We also thank Professor Richard B. 
Johnston, Jr., who introduced us to macrophages and oxygen radicals. This 
work was supported by NIH grant R01 DE05494 to MJP, and by a Univer-
sity of Tennessee College of Dentistry Alumni grant to DBH and MJP. SBG 
and FG thank Dr. Yingxin Zhao for experimental assistance. Funds for the 
mass spectrometers were provided by NIH grants RR10522, RR14593, 
DBI960-4633, and by the UTHSC College of Pharmacy.
References
1. Cummings NP, Pabst MJ, Johnston RB Jr.: Activation of macro-
phages for enhanced release of superoxide anion and greater
killing of Candida albicans by injection of muramyl dipeptide
.  J Exp Med 1980, 152:1659-1669.
2. Chedid L, Parant M, Parant F, Lefrancher P, Choay J, Lederer E:
Enhancement of nonspecific immunity to Klebsiella pneu-
moniae infection by a synthetic immunoadjuvant (N-acetyl-
muramyl-L-alanyl-D-isoglutamine) and several analogs .  Proc
Natl Acad Sci U S A 1977, 74:2089-2093.
Additional File 1
2D gel image from unprimed monocytes (No LPS). 2D gel from mono-
cytes incubated for 16 h with no addition. Stained with Sypro ruby. Spots 
(or the positions of missing spots) are located just to the left of the identi-
fying letters.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1477-
5956-6-13-S1.pdf]
Additional File 2
2D gel image from monocytes primed with LPS. 2D gel from monocytes 
exposed to LPS (2 ng/ml) for 16 h.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1477-
5956-6-13-S2.pdf]
Additional File 3
2D gel image from unprimed monocytes treated with AEBSF. 2D gel 
from monocytes exposed to AEBSF (250 µM) for 16 h in the absence of 
LPS.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1477-
5956-6-13-S3.pdf]
Additional File 4
2D gel image from monocytes primed with LPS and treated with 
AEBSF. 2D gel from monocytes exposed to AEBSF (250 µM) for 16 h in 
the presence of LPS.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1477-
5956-6-13-S4.pdf]
Additional File 5
Histograms of 30 differentially expressed protein spots in 2D gels from 
monocytes treated ± LPS ± AEBSF. The first bar is Time 0, a control from 
monocytes taken at the start of culture. The second bar is No LPS for 16 
h, third bar is LPS for 16 h, fourth bar is AEBSF alone for 16 h, and fifth 
bar is LPS + AEBSF for 16 h. The sixth bar shows the effect of AEBSF 
added at the end of culture at 16 h to monocytes not treated with LPS, 
and the seventh bar shows AEBSF added at the end of culture to monocytes 
exposed to LPS for 16 h. Four patterns of expression were observed: yellow 
background indicates proteins whose expression increased in response to 
AEBSF, pink indicates proteins that decreased with AEBSF, blue indicates 
proteins that decreased with LPS, and green indicates proteins that 
increased with LPS.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1477-
5956-6-13-S5.pdf]Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
Proteome Science 2008, 6:13 http://www.proteomesci.com/content/6/1/13
Page 13 of 13
(page number not for citation purposes)
3. Megyeri P, Pabst KM, Pabst MJ: Serine protease inhibitors block
priming of monocytes for enhanced release of superoxide .
Immunology 1995, 86:629-635.
4. McIntire FC, Barlow GH, Sievert HW, Finley RA, Yoo AL: Studies
on a lipopolysaccharide from Escherichia coli. Heterogeneity
and mechanism of reversible inactivation by sodium deoxy-
cholate .  Biochemistry 1969, 8:4063-4067.
5. Pabst MJ, Hedegaard HB, Johnston RB Jr.: Cultured human mono-
cytes require exposure to bacterial products to maintain an
optimal oxygen radical response .  J Immunol 1982, 128:123-128.
6. Le Naour F, Hohenkirk L, Grolleau A, Misek DE, Lescure P, Geiger
JD, Hanash S, Beretta L: Profiling changes in gene expression
during differentiation and maturation of monocyte-derived
dendritic cells using both oligonucleotide microarrays and
proteomics .  J Biol Chem 2001, 276:17920-17931.
7. Jin M, Opalek JM, Marsh CB, Wu HM: Proteome comparison of
alveolar macrophages with monocytes reveals distinct pro-
tein characteristics .  Am J Respir Cell Mol Biol 2004, 31:322-329.
8. Juan HF, Lin JY, Chang WH, Wu CY, Pan TL, Tseng MJ, Khoo KH,
Chen ST: Biomic study of human myeloid leukemia cells dif-
ferentiation to macrophages using DNA array, proteomic,
and bioinformatic analytical methods .  Electrophoresis 2002,
23:2490-2504.
9. Forehand JR, Pabst MJ, Phillips WA, Johnston RB Jr.: Lipopolysac-
charide priming of human neutrophils for an enhanced res-
piratory burst. Role of intracellular free calcium .  J Clin Invest
1989, 83:74-83.
10. Kitagawa S, Yuo A, Yagisawa M, Azuma E, Yoshida M, Furukawa Y,
Takahashi M, Masuyama J, Takaku F: Activation of human mono-
cyte functions by tumor necrosis factor: rapid priming for
enhanced release of superoxide and erythrophagocytosis,
but no direct triggering of superoxide release .  Exp Hematol
1996, 24:559-567.
11. Yuo A, Kitagawa S, Motoyoshi K, Azuma E, Saito M, Takaku F: Rapid
priming of human monocytes by human hematopoietic
growth factors: granulocyte-macrophage colony-stimulating
factor (CSF), macrophage-CSF, and interleukin-3 selectively
enhance superoxide release triggered by receptor-mediated
agonists .  Blood 1992, 79:1553-1557.
12. Duerst R, Werberig K: Cells of the J774 macrophage cell line
are primed for antibody-dependent cell-mediated cytotoxic-
ity following exposure to gamma-irradiation .  Cell Immunol
1991, 136:361-372.
13. Lambert LE, Paulnock DM: Modulation of macrophage function
by gamma-irradiation. Acquisition of the primed cell inter-
mediate stage of the macrophage tumoricidal activation
pathway .  J Immunol 1987, 139:2834-2841.
14. Carozzi S, Caviglia PM, Nasini MG, Schelotto C, Santoni O, Pietrucci
A: Peritoneal dialysis solution pH and Ca2+ concentration
regulate peritoneal macrophage and mesothelial cell activa-
tion .  Asaio J 1994, 40:20-23.
15. Speer CP, Pabst MJ, Hedegaard HB, Rest RF, Johnston RB Jr.:
Enhanced release of oxygen metabolites by monocyte-
derived macrophages exposed to proteolytic enzymes:
activity of neutrophil elastase and cathepsin G .  J Immunol
1984, 133:2151-2156.
16. Szefler SJ, Norton CE, Ball B, Gross JM, Aida Y, Pabst MJ: IFN-
gamma and LPS overcome glucocorticoid inhibition of prim-
ing for superoxide release in human monocytes. Evidence
that secretion of IL-1 and tumor necrosis factor-alpha is not
essential for monocyte priming .  J Immunol 1989,
142:3985-3992.
17. Gadgil HS, Pabst KM, Giorgianni F, Umstot ES, Desiderio DM,
Beranova-Giorgianni S, Gerling IC, Pabst MJ: Proteome of mono-
cytes primed with lipopolysaccharide: Analysis of the abun-
dant proteins .  Proteomics 2003, 3:1767-1780.
18. Benes P, Maceckova V, Zdrahal Z, Konecna H, Zahradnickova E,
Muzik J, Smarda J: Role of vimentin in regulation of monocyte/
macrophage differentiation .  Differentiation 2006, 74:265-276.
19. Jin M, Diaz PT, Bourgeois T, Eng C, Marsh CB, Wu HM: Two-dimen-
sional gel proteome reference map of blood monocytes .  Pro-
teome Sci 2006, 4:16.
20. Hu J, Jacinto R, McCall C, Li L: Regulation of IL-1 receptor-asso-
ciated kinases by lipopolysaccharide.  J Immunol 2002,
168:3910-3914.
21. Nakabo Y, Pabst MJ: Lysis of leukemic cells by human macro-
phages: inhibition by 4-(2-aminoethyl)-benzenesulfonyl fluo-
ride (AEBSF), a serine protease inhibitor .  J Leukoc Biol 1996,
60:328-336.
22. Nakabo Y, Pabst MJ: C2-ceramide and C6-ceramide inhibited
priming for enhanced release of superoxide in monocytes,
but had no effect on the killing of leukaemic cells by mono-
cytes .  Immunology 1997, 90:477-482.
23. Southan C: Has the yo-yo stopped? An assessment of human
protein-coding gene number .  Proteomics 2004, 4:1712-1726.
24. Lee C, Park DW, Lee J, Lee TI, Kim YJ, Lee YS, Baek SH: Secretory
phospholipase A2 induces apoptosis through TNF-alpha and
cytochrome c-mediated caspase cascade in murine macro-
phage RAW 264.7 cells .  Eur J Pharmacol 2006, 536:47-53.
25. Suen YK, Fung KP, Choy YM, Lee CY, Chan CW, Kong SK: Conca-
navalin A induced apoptosis in murine macrophage PU5-1.8
cells through clustering of mitochondria and release of cyto-
chrome c .  Apoptosis 2000, 5:369-377.
26. Dougherty GW, Chopp T, Qi SM, Cutler ML: The Ras suppressor
Rsu-1 binds to the LIM 5 domain of the adaptor protein
PINCH1 and participates in adhesion-related functions .  Exp
Cell Res 2005, 306:168-179.
27. Kim JW, Kim C: Inhibition of LPS-induced NO production by
taurine chloramine in macrophages is mediated though Ras-
ERK-NF-kappaB .  Biochem Pharmacol 2005, 70:1352-1360.
28. Megyeri P, Nemeth L, Pabst KM, Pabst MJ, Deli MA, Abraham CS: 4-
(2-Aminoethyl)benzenesulfonyl fluoride attenuates tumor-
necrosis-factor-alpha-induced blood-brain barrier opening .
Eur J Pharmacol 1999, 374:207-211.
29. The universal protein resource (UniProt)  Nucleic Acids Res
2008, 36:D190-195 [http://beta.uniprot.org].
30. Tannu NS, Wu J, Rao VK, Gadgil HS, Pabst MJ, Gerling IC, Raghow R:
Paraffin-wax-coated plates as matrix-assisted laser desorp-
tion/ionization sample support for high-throughput identifi-
cation of proteins by peptide mass fingerprinting .  Anal
Biochem 2004, 327:222-232.
31. Baker PR, Clauser KR: MS-Fit.   [http://prospector.ucsf.edu].
32. Mascot   [http://www.matrixscience.com]